A study to investigate safety, tolerability, and pharmacokinetics of oral AZD0233 compared with placebo in healthy adult participants.

Study identifier:D7250C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A Phase I, Randomized, Single blinded, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD0233 Following Single and Multiple Ascending Dose Administration in Healthy Male and Female Participants 18 to 50 years of age.

Medical condition

Dilated cardiomyopathy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD0233, AZD0233 Placebo

Sex

All

Estimated Enrollment

96

Study type

Interventional

Age

18 Years - 50 Years

Date

Study Start Date: 01 Apr 2024
Estimated Primary Completion Date: 20 Mar 2025
Estimated Study Completion Date: 20 Mar 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria